The pharmacokinetics of taurolidine metabolites in healthy volunteers

Journal of Clinical Pharmacology

Volumn 47, Issue 6, 2007, Pages 697-703

  Gong, Li ^a   Greenberg, Howard E ^a   Perhach, James L ^b   Waldman, Scott A ^a   Kraft, Walter K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Healthy volunteers; Pharmacokinetics; Taurinamide; Taurolidine; Taurultam

Indexed keywords

TAUROLIDINE; TAURULTAM;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; EPISTAXIS; FEMALE; FLUSHING; HUMAN; INJECTION SITE BURNING; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; MALE; NAUSEA; NORMAL HUMAN; SIDE EFFECT; SINGLE DRUG DOSE;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; PHARMACEUTIC AIDS; POVIDONE; TAURINE; THIADIAZINES;

EID: 34249048186     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007299929     Document Type: Article

References (22)

1. Browne MK, Leslie GB, Pfirrmann RW, Brodhuge H. The in vitro and in vivo activity of Taurolin against anaerobic pathogenic organisms. Surg Gynecol Obstet. 1977 ; 145: 842-846.
2. Knight BI, Skellern GG, Smail GA, et al. NMR studies and GC analysis of the antibacterial agent, taurolidine. J Pharm Sci. 1983 ; 72: 705-707.
3. Browne MK Pharmacological and clinical studies on Taurolin. In: Bruckner WL, Pfirrmann RW, eds. A New Concept in Antimicrobial Chemotherapy for Surgical Infection. Baltimore: Urban & Schwarzenberg ; 1985: 51-63.
4. Browne MK The treatment of peritonitis by an antiseptic- Taurolin. Pharmatherapeutica. 1981 ; 2: 517-522.
5. Blenkharn JJ Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S). J Pharmacol. 1988 ; 40: 509-511.
6. Gorman SP, McCafferty DF, Woolfson AD, Junes DS Electron microscope observations of bacterial cell surface effects due to taurolidine treatment. Lett Appl Microbiol. 1987 ; 4: 103-109.
7. Monson JR, Ramsey PS, Donohue JH Taurolidine inhibits tumor necrosis factor (TNF) toxicity: new evidence of TNF and endotoxin synergy. Eur J Surg Oncol. 1993 ; 3: 226-231.
8. Watson RW, Redmond HP, McCarthy J., Bouchier-Hayes D. Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by amino acid taurine. J Leukoc Biol. 1995 ; 58: 299-306.
9. Leithauser ML, Rob PM, Sack K. Pentoxifylline, cyclosporine A and taurolidine inhibit endotoxin-stimulated tumor necrosis factor-alpha production in rat mesangial cell cultures. Exp Nephrol. 1997 ; 1: 100-104.
10. Willatts SM, Radford S., Leitermann M. Effect of the antiendotoxin agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit Care Med. 1995 ; 23: 1033-1039.
11. Jacobi CA, Peter FJ, Wenger FA, et al. New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. Dig Surg. 1999 ; 16: 393-399.
12. McCourt M., Wang JH, Sookhai S., Redmond HP Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol. 2000 ; 7: 685-691.
13. Calabresi P., Goulette FA, Darnowski JW Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res. 2001 ; 61: 6816-6821.
14. Nestler G., Schulz HU, Schubert D., et al. Impact of taurolidine on the growth of CC531 colon carcinoma cells in vitro and in a laparoscopic animal model in rats. Surg Endosc. 2005 ; 19: 280-284.
15. Da Costa ML, Redmond HP, Bouchier-Hayes DJ Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. J Surg Res. 2001 ; 101: 111-119.
16. Braumann C., Ordemann J., Kilian M., et al. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis. 2003 ; 20: 387-394.
17. Jacobi CA, Menenakosa C., Braumann C. Taurolidine: a new drug with anti-tumor and anti-angiogenic effects. Anti-Cancer Drugs. 2005 ; 16: 917-921.
18. Nici L., Monfils B., Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res. 2004 ; 10: 7655-7661.
19. Erb F., Imbenotte M., Huvenne JP, et al. Structural investigation of a new organic antiseptic: taurolidine. Analytical study and application to identification and quantitation in biological fluids. Eur J Drug Metab Pharmacokinet. 1983 ; 8: 163-173.
20. Woolfson AD, Gorman SP, McCafferty DF, Jones DS Assay procedures for Taurolin solutions using pre-column derivatisation and high-performance liquid chromatography with fluorescence detection. Int J Pharmaceutics. 1989 ; 49: 135-140.
21. Gorman SP, McCafferty DF, Woolfson AD, Junes DS Electron microscope observations of bacterial cell surface effects due to taurolidine treatment. Lett Appl Microbiol. 1987 ; 4: 103-109.
22. Braumann C., Winkler G., Rogalla P., et al. Prevention of disease progression in a patient with a gastric cancer-recurrence: outcome after intravenous treatment with the novel antineoplastic agent taurolidine. World J Surg Oncol. 2006 ; 4: 34-39.